Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06447506 · ClinicalTrials.gov registry record · Phase 2
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT06447506 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 79 participants.
The verdict
NCT06447506, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
Interventions
- DRUG Placebo
- DRUG GSK1070806
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2025-07-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06447506
The ClinicalTrials.gov registry entry for NCT06447506 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06447506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06447506 about?
NCT06447506 is a clinical study titled "Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.". The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
What is the current status of trial NCT06447506?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2024-06-05. Estimated completion is 2025-07-29.
What interventions are being tested in trial NCT06447506?
The interventions under investigation include: Placebo (DRUG), GSK1070806 (DRUG).
Who is sponsoring clinical trial NCT06447506?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.